Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$1.90 -0.5%	$1.94	$1.60 ▼ $2.54	$736.65M	1.04	1.34 million shs	885,477 shs
EDIT Editas Medicine	$2.28 +7.5%	$1.76	$0.91 ▼ $6.05	$177.47M	2.1	2.58 million shs	5.46 million shs
PHAR Pharming Group	$10.83 +0.1%	$10.21	$6.65 ▼ $12.61	$736.09M	0.02	6,073 shs	5,739 shs
REPL Replimune Group	$9.33 -1.4%	$9.00	$6.44 ▼ $17.00	$729.24M	0.63	863,328 shs	1.40 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	-0.52%	+2.15%	-5.94%	+6.15%	-18.10%
EDIT Editas Medicine	+7.55%	+2.70%	+21.93%	+82.40%	-52.60%
PHAR Pharming Group	+0.80%	+2.13%	+5.31%	+29.25%	+33.82%
REPL Replimune Group	-1.37%	+0.65%	+10.68%	-10.20%	+7.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	2.4195 of 5 stars	0.0	5.0	0.0	2.5	0.0	2.5
EDIT Editas Medicine	3.8512 of 5 stars	3.2	2.0	4.2	1.4	2.5	0.6
PHAR Pharming Group	2.3357 of 5 stars	3.5	3.0	0.0	2.9	0.0	0.6
REPL Replimune Group	4.2425 of 5 stars	3.6	3.0	4.5	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
EDIT Editas Medicine	2.31	Hold	$4.70	106.14% Upside
PHAR Pharming Group	3.00	Buy	$30.00	177.11% Upside
REPL Replimune Group	3.13	Buy	$20.83	123.29% Upside

Current Analyst Ratings Breakdown

Latest EDIT, PHAR, REPL, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.23	$0.00 per share	4,104.70	$2.90 per share	0.66
EDIT Editas Medicine	$32.31M	5.91	N/A	N/A	$1.63 per share	1.40
PHAR Pharming Group	$297.20M	2.48	$0.07 per share	145.96	$3.25 per share	3.33
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	14.62	63.33	32.48	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	360.87	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/6/2025 (Estimated)

Latest EDIT, PHAR, REPL, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
EDIT Editas Medicine	N/A	3.08	3.08
PHAR Pharming Group	0.39	2.76	2.00
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
EDIT Editas Medicine	71.90%
PHAR Pharming Group	0.03%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
EDIT Editas Medicine	2.10%
PHAR Pharming Group	2.07%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	357.53 million	Optionable
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable

EDIT, PHAR, REPL, and CRON Headlines

Recent News About These Companies

Replimune Group, Inc. (NASDAQ:REPL) Receives $20.83 Consensus Price Target from Analysts

3 hours ago | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

June 25 at 4:26 AM | marketbeat.com

Cantor Fitzgerald Begins Coverage on Replimune Group (NASDAQ:REPL)

June 22, 2025 | americanbankingnews.com

Cantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight Recommendation

June 20, 2025 | msn.com

Replimune Group (NASDAQ:REPL) Coverage Initiated at Cantor Fitzgerald

June 20, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE

June 14, 2025 | marketbeat.com

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.comQ

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Wellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)

June 3, 2025 | marketbeat.com

Piper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

June 2, 2025 | marketbeat.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

June 1, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

June 1, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?

May 31, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's Why

May 30, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC

May 30, 2025 | marketbeat.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings

May 24, 2025 | uk.investing.com

REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings

May 24, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
By Jeffrey Neal Johnson | May 29, 2025
View Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

EDIT, PHAR, REPL, and CRON Company Descriptions

Cronos Group NASDAQ:CRON

$1.90 -0.01 (-0.52%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.90 0.00 (-0.26%)

As of 06/27/2025 07:27 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Editas Medicine NASDAQ:EDIT

$2.28 +0.16 (+7.55%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.24 -0.04 (-1.75%)

As of 06/27/2025 07:55 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Pharming Group NASDAQ:PHAR

$10.83 +0.01 (+0.06%)

Closing price 06/27/2025 03:57 PM Eastern

Extended Trading

$10.82 0.00 (-0.01%)

As of 06/27/2025 04:04 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Replimune Group NASDAQ:REPL

$9.33 -0.13 (-1.37%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.33 0.00 (0.00%)

As of 06/27/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time